ClinicalTrials.gg
RecruitingNCT06823700Updated Feb 12, 2025

Safety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU

An interventional study of SQ-Kyrin Transcatheter Mitral Valve Repair System in Functional Mitral Regurgitation, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Mitral Valve Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Mitral Valve Insufficiency · Spain.

Planned enrollment
9th of 12
34 · median 204
Started
2024
with 2 others
No phase
11 of 20
7 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
16th of 20
by date

Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 16th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

11 of the 20 studies in Mitral Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Mitral Valve Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

The investigation objective of this study is to evaluate the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in the population of FMR patients and the accessories devices when used in conjunction with the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter.

Read the detailed description

The primary objective is to verify the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter produced by Shanghai Shenqi Medical Technology Co., Ltd. In the treatment of patients with moderate-severe (3 +) or severe (4 +) FMR whose symptoms and MR severity persist despite maximally tolerated GDMT as determined by a multidisciplinary heart team experienced in the evaluation and treatment of heart failure and mitral valve disease.

03

Conditions studied

  • Functional Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant who has provided written for the investigation.
  2. Age ≥18 years.
  3. Patients diagnosed with FMR.
  4. MR severity is (functional) ≥3+ as determined by transthoracic echocardiography (TTE).
  5. ≥20% to ≤60%.
  6. Symptom status: functional class II to IV despite a stable maximally tolerated GDMT regimen as per guidelines.
  7. According to the judgment of local cardiology team, subjects have undergone adequate treatment for at least 30 days (preferably 90 days) based on the criteria recommended in the heart failure guidelines.
  8. Subject fulfils FMR anatomy selection criteria.
  9. According to the judgment of the local Cardiovascular medical-surgery team, subjects who have high or prohibitive risk for open heart surgery.
  10. Left ventricular end-systolic diameter (LVESD)≤70mm.
  11. The MR beam mainly originates from the A2/P2 area.
  12. Mitral valve coaptation depth≤11mm, coaptation height≥2mm, effective length of anterior and posterior leaflets>10mm.
  13. Mitral valve effective orifice area (EOA) ≥ 4.0cm2.
  14. No obvious calcification of main grasp mitral valve leaflets.
  15. Patient anatomy allows atrial septum approach.

Exclusion criteria

Exclusion Criteria:

  1. \<1 year due to non-cardiac conditions or heart failure deemed suitable for palliative treatment.
  2. Hypotension (systolic pressure \<90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support.
  3. UNOS status 1 heart transplantation or prior orthotopic heart transplantation.
  4. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology.
  5. Fixed pulmonary artery systolic pressure >70 mm Hg.
  6. Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction.
  7. Mitral valve anatomy which may preclude proper device treatment.
  8. Mitral valve area \< 4.0 cm2 (if new device therapy may further decrease the mitral orifice area).
  9. Any prior mitral valve surgery or transcatheter mitral valve procedure.
  10. Stroke or transient ischemic event within 30 days before enrolment.
  11. Modified Rankin ≥ Scale 4 disability.
  12. Severe symptomatic carotid stenosis (>70% by ultrasound).
  13. Need for emergent or urgent intervention for any reason or any planned cardiac intervention within the next 12 months.
  14. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within 1 month before enrolment.
  15. Untreated coronary artery disease requiring revascularization.
  16. Any percutaneous cardiovascular intervention, cardiovascular intervention, or carotid intervention within 30 days
  17. Tricuspid valve disease requiring intervention or severe or more tricuspid regurgitation.
  18. Aortic valve disease requiring intervention or any concomitant treatment.
  19. Need for any cardiovascular intervention (other than for MV disease).
  20. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
  21. Active endocarditis.
  22. Active infections requiring current antibiotic therapy.
  23. Subjects in whom transoesophageal echocardiography is or high risk.
  24. Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits.
  25. Patient unable or unwilling to provide written, before study enrolment.
  26. Pregnant woman or woman planning to become pregnant.
  27. Patients with severe liver, renal or pulmonary disease, which in investigator opinion may have an impact on patient safety.
  28. Clinically significant lab abnormalities which in investigator opinion may have an impact on patient safety.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    SQ-Kyrin TMVr System

    Device: SQ-Kyrin Transcatheter Mitral Valve Repair System

Interventions

  • DeviceSQ-Kyrin Transcatheter Mitral Valve Repair System

    To percutaneously repair the mitral valve via the femoral vein and atrial septum, offering a treatment for symptomatic functional mitral regurgitation through edge-to-edge valve clipping.

06

What researchers measure

Primary outcomes

  1. Number of patients with composite measures- All-cause death and recurrent hospitalizations due to heart failure

    A composite of all-cause death and recurrent hospitalizations due to heart failure

    Time frame: 12 months

Secondary outcomes

  1. Technical success rate

    Defined by the following four conditions: 1. No procedural mortality. 2. Successful delivery, implant, retrieval of the delivery system. 3. Successful devices release. 4. No need for any emergency surgery related to the device or surgical approach.

    Time frame: immediately after intervention

  2. Device success rate

    Defined by the following three conditions: 1. Technical success maintained at day 30. 2. Transthoracic echocardiographic assessment showing MR ≤2+ without significant mitral stenosis. 3. No structural or functional failure of the device.

    Time frame: 30 days

  3. Procedural success rate

    Defined by following two conditions: 1. Device success. 2. No major adverse events occurred.

    Time frame: 30 days

  4. The rate of New York Heart Association (NYHA) heart function class I or II

    Time frame: On the day of discharge, 30 days, 6 months, and 12 months

  5. Improvement in quality of life from baseline

    Improvement in quality of life (QoL) at 12 months over baseline, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, scale from 0 - 100, and higher scores mean a better outcome.

    Time frame: 12 months

  6. Rate of MR 2+ or less than 2+

    Mitral regurgitation severity grade 2+ or less than 2+

    Time frame: 30 days, 6 months, and 12 months

  7. Change from baseline to discharge in MR severity assessed by echocardiography.

    Time frame: On the day of discharge

  8. Rate of hospitalization for heart failure

    Time frame: 30 days, 6 months, and 12 months

  9. Improvement by ≥ 50m in 6-minute walk distance from baseline

    Time frame: 12 months

  10. Improvement in left ventricular end-diastolic volume (LVEDV) from baseline

    Time frame: 12 months

  11. Incidence of all-cause mortality

    Time frame: 30 days, 6 months, and 12 months

  12. Cardiovascular-related mortality

    Time frame: 30 days, 6 months, and 12 months

  13. Incidence of major adverse events

    The major adverse event refers to the composite endpoint of death, stroke, myocardial infarction, and cardiovascular surgery due to device- or interventional-related adverse events that occurred since successful transfemoral vein puncture and establishment of atrial septal pathway.

    Time frame: 30 days and 12 months

07

Study locations

1 of 1 sites recruiting
  • Hospital Clínico Universitario de Valladolid
    Valladolid, 47003, Spain
    Recruiting
    • Ignacio J Amat-Santos, MD, Ph.D · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 24 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Feb 12, 2025
StartActual
Dec 17, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06823700
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Dec 17, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 12, 2025

Study contacts

Clinical Director
Contact
chaojun.gu@sqmedical.com
+86 13636491192
Ignacio J Amat-Santos, MD, Ph.D
principal investigator · Hospital Clínico Universitario de Valladolid

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion